

1 Claims

2

3 1. An implantable medicament delivery device which
4 is insertable into the female uterine myometrium or
5 the male prostate gland comprising means capable of
6 providing controlled delivery of a medicament over a
7 period of time.

8

9 2. An implantable medicament delivery device as
10 claimed in claim 1 comprising

11

12 a body having an outer surface and opposing
13 ends wherein a first end of the body has a
14 semi-sharp point.

15

16 3. An implant as claimed in claim 1 or 2 wherein
17 the implant is absorbable.

18

19 4. A device as claimed in claim 2 or 3 wherein the
20 body is elongate and at the second end includes a
21 head portion wherein the head portion is a lateral
22 extension from the longitudinal axis of the elongate
23 body.

24

25 5. The device of claim 4 wherein the head portion
26 is a substantially flat plate which extends in all
27 radial directions from the second end of the body of
28 the device.

29

30 6. A device as claimed in claim 4 or 5 wherein, in
31 use, the head portion allows manipulation and
32 surveillance of the implant.

1 7. The device of any preceding claim wherein the
2 means capable of providing controlled delivery of a
3 medicament are provided in or on the body of the
4 implant.

5

6 8. The device of any of claims 4 to 7 wherein the
7 means capable of providing controlled delivery of a
8 medicament are provided in or on the head portion of
9 the implant.

10

11 9. The device of any of claims 2 to 8 wherein the
12 second end comprises retrieval means.

13

14 10. The device of any preceding claim wherein the
15 device retrieval means is an elongate flexible
16 member.

17

18 11. The device according to any preceding claim
19 which has an axial length from 5 mm to 45 mm.

20

21 12. The device according to any preceding claim
22 which has a diameter of from 0.5 mm to 4 mm.

23

24 13. A device according to any preceding claim
25 comprising at least one medicament.

26

27 14. The device as claimed in claim 13 wherein the
28 least one medicament is selected from anti-
29 infectives, antimicrobials, prebiotics, probiotics,
30 acidifiers, antivirals, antibiotics, anti-
31 allergenics, anti-inflammatories, anti-fungals,
32 anti-cholinesterases, nutritional agents,

1 cardiovascular agents, anti-hypertensive agents and
2 chemotherapeutic agents.

3

4 15. The device as claimed in claim 13 or 14 wherein
5 the device comprises a medicament for oestrogen
6 dependent proliferative disorders of the pelvis for
7 example endometriosis or fibroids.

8

9 16. The device according to any one of claims 13 to
10 15 wherein said the medicament is at least one
11 member chosen from the group including progestins,
12 GnRH agonists / antagonists, NSAIDs, COX-II
13 inhibitors, combined oral contraceptives, Danazol,
14 smooth muscle relaxants or aromatase inhibitors.

15

16 17. The device according to any preceding claim
17 wherein, in use, the cumulative release of
18 medicament is in an amount selected from 5%, 10%,
19 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
20 95% or 99% relative to the total amount of
21 medicament in the device after implantation for a
22 period of 1 day, 1 week, 2 weeks, 1 month, 2 months,
23 3 months, 4 months, 6 months, 1 year, 2 years, 3
24 years, 4 years or 5 years.

25

26 18. A kit for implanting a device as claimed in any
27 of claims 1 to 17 comprising

28 a device as claimed in any of claims 1 to 15;

29 and

30 an insertion tool comprising an elongate shaft,
31 said shaft having a handle means at a first end
32 thereof and device mounting means at a second

1 opposite end wherein the medicament delivery
2 device is mountable on the device mounting
3 means of the insertion tool.

4

5 19. A method for introducing a medicament into the
6 body of a female mammal, comprising the step of
7 inserting a device according to claims 1 to 17 into
8 the myometrium.

9

10 20. A method as claimed in claim 19 comprising the
11 steps of

- 12 - providing the implantable medicament
- 13 delivery device of claims 1 to 15;
- 14 - introducing the medicament delivery device
- 15 into the body via the vagina;
- 16 - penetrating the myometrium; and
- 17 - inserting the medicament delivery device
- 18 into the myometrium.

19

20 21. The method as claimed in claim 20 wherein the
21 medicament implantable device is introduced into the
22 body using an insertion tool.

23

24 22. Use of an implantable medicament delivery
25 device as claimed in claims 1 to 17 to provide long
26 term local delivery of medicaments to the vaginal
27 cavity and epithelium and thereby into the pelvic
28 region and organs thereof including to the bladder,
29 peritoneum, vulva, vagina, ovaries, fallopian tubes
30 and/or the uterus and/or then into the bloodstream.

31

1 23. Use of an implantable medicament delivery
2 device as claimed in claims 1 to 17 to provide long
3 term local delivery of medicaments to the myometrium
4 and thereby into the pelvic region and organs
5 thereof including to the bladder, peritoneum, vulva,
6 vagina, ovaries, fallopian tubes and/or the uterus
7 and/or then into the bloodstream.

8
9 24. Use of an implantable delivery device as
10 claimed in claims 1 to 17 to provide long term local
11 delivery of medicaments to the prostate gland,
12 seminal vesicles, rectum, bladder and/or tissues
13 and/or pelvic region and/or organs thereof and/or
14 then into the bloodstream.